By Jennifer Ahlstrom | Posted - Oct 18th, 2013

 

 

 

 

Stanford Research Institute creating an anti-angiogenic model for multiple myeloma

A friend sent me this link to Stanford Research Institute's work in the development of an anti-angiogenic molecule, SR16388. Studies show that this molecule prevents angiogenesis (or new blood vessel development) and the growth of multiple myeloma cells. The new molecule is currently under development and is getting ready for early patient clinical trials. Click Here to read the SRI International article.

 
Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio, HealthTree and the CrowdCare Foundation.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

.